ATXS Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Astria Therapeutics | Updated today | Last updated: 2026-07-27

TickerATXS

Market Capn/a

Cash RunwayUnknown

Next Catalyst2027-03

Public Research Snapshot

Astria Therapeutics is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Navenibart in Hereditary Angioedema (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Navenibart	Hereditary Angioedema	n/a	Phase 3	Public pipeline row
STAR-0310	Healthy Participants	n/a	Phase 1	Public pipeline row
STAR-0215 (SC)	Hereditary Angioedema	n/a	Phase 1	Public pipeline row
STAR-0215	Hereditary Angioedema	n/a	Phase 2	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-03	Navenibart	Low
		Clinical Trial Completion	2031-03	STAR-0215	Low

Cash Runway Preview

Estimated cash runway: Unknown.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT05477160	Phase 1	COMPLETED	41	2023-11-17
NCT05695248	Phase 1 \| Phase 2	COMPLETED	29	2025-03-13
NCT06782477	Phase 1	ACTIVE_NOT_RECRUITING	40	2026-01
NCT06842823	Phase 3	RECRUITING	145	2027-03
NCT06007677	Phase 2	ACTIVE_NOT_RECRUITING	56	2031-03

Scientific Context

literature_publication | Onset and depth of response with abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis, including prominent head-and-neck dermatitis: A post hoc analysis of the head-to-head phase 3 JADE DARE study.
literature_publication | Renal Disease Burden in Prurigo Nodularis: A Systematic Review and Meta-Analysis.
literature_publication | Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary Angioedema.
literature_publication | Interleukin-4-producing type 2 innate lymphoid cells in the lymph node promote proallergic Tfh13 cell differentiation.
literature_publication | Corticosteroid-Associated Adverse Events in Chronic Spontaneous Urticaria: A US Claims Data Study.

Want the full ATXS research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.